This inventor holds 3 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Chinese Academy of Sciences, Shanghai Hyamab Biotech Co., Ltd., Van Andel Research Institute. Active years: 2025-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 3,363 
1 out of 1 
1 out of 26 
Years Active: 2025-2026
Title: The Innovative Contributions of Rongrong Xie in Pharmaceuticals
Introduction
Rongrong Xie, an accomplished inventor based in Shanghai, China, has made significant strides in the field of pharmaceuticals. With a focus on developing compounds that target specific diseases, her innovative work has garnered attention and potential for improving therapeutic options.
Latest Patents
Rongrong Xie holds one patent for an FXR small molecule agonist. The patent, known as "FXR small molecule agonist and preparation method therefor and use thereof," describes a compound that demonstrates FXR agonistic activity, which is critical for developing drugs intended to treat FXR-related diseases. The chemical structure of this compound is detailed in formula (I), highlighting its potential applications in healthcare.
Career Highlights
Her professional journey includes significant roles at prestigious institutions such as the Chinese Academy of Sciences and the Van Andel Research Institute. Through these positions, she has contributed to a wide range of research projects aimed at enhancing drug development and understanding disease mechanisms.
Collaborations
Throughout her career, Rongrong Xie has collaborated with notable researchers, including Huaqiang Xu and Jia Tao Li. These partnerships have enriched her research and fostered innovative solutions in the field of pharmaceutical sciences.
Conclusion
Rongrong Xie's remarkable patent and her collaboration with distinguished colleagues emphasize her role as an influential inventor in the pharmaceutical industry. Her work not only contributes to better therapeutic outcomes but also inspires future innovations in drug development.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile